| Literature DB >> 9987152 |
M L Herlocher1, M Ewasyshyn, S Sambhara, M Gharaee-Kermani, D Cho, J Lai, M Klein, H F Maassab.
Abstract
Respiratory syncytial virus (RSV) causes severe lower respiratory tract disease in infants, young children, and the elderly. Efforts to develop satisfactory live or inactivated vaccines have not yet been proven successful. Our research focuses on the development of four purified live attenuated RSV sub-type A human vaccine clones. Temperature sensitive (ts) and attenuated purified clones of either cold-adapted (ca) RSV or high-passage (hp) RSV were administered intra-nasally (i.n.) to BALB/c mice and tested for immunogenicity. All four clones produced significant anti-RSV F IgG2a and IgG1 titres in the sera of mice, RSV-specific neutralizing titres higher than those produced by their wild-type progenitor viruses, cytotoxic T-lymphocyte (CTL) activity, and total protection against wild-type (wt) viral challenge. These purified vaccine candidates await testing in humans to determine which contain the required balance between immunogenicity and attenuation.Entities:
Mesh：
Substances：
Year: 1999 PMID： 9987152 DOI： 10.1016/s0264-410x(98)00155-8
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641